Advanced/Metastatic Pancreatic Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Pancreatic cancer that cannot be found or surgically removed is considered advanced or metastatic. To some extent outside the pancreas, to nearby lymph nodes, to far-off organs, or to both, the cancer has spread (metastasized). Usually, the third or fourth stage is this one. The majority of people with pancreatic cancer have advanced forms of the disease. The 11th leading cause of cancer morbidity and the 7th leading cause of cancer-related death worldwide, respectively, are pancreatic cancer. ASR, or average lifetime incidence rate, ranges from 7 to 15. In contrast to 2, there are 7 per 100,000 people in Europe. 2 for every 100,000 in Africa. Across countries, the ASR ranged from 0 to. Between the ages of 15 and 24, 81 men out of every 100,000 in India. 3 per 100,000 men in the Republic of Moldova and Latvia.

Description

Pancreatic cancer that cannot be found or surgically removed is considered advanced or metastatic. The cancer has spread (metastasized) to nearby lymph nodes or blood vessels, to distant organs, or outside the pancreas. In most cases, this is the third or fourth stage. Most people who are diagnosed with pancreatic cancer have advanced forms of the disease. Even if the cancer has spread, patients who receive an early diagnosis still risk developing advanced cancer. When cancer has spread to an additional organ or tissue, it is said to have metastatic disease. The liver, abdominal wall, lungs, bones, or distant lymph nodes are the places where pancreatic cancer spreads most frequently. Early diagnosis is challenging due to the disease's asymptomatic early stages, as approx. Only after the disease has locally advanced or metastasized are 80-85% of patients diagnosed. The prognosis of pancreatic cancer worsens as it spreads to the liver, stomach lining, and eventually the intestines as the disease advances. Worst case scenario: it spreads to the lungs. A minimum of one year or less is the median length of survival for patients with metastatic pancreatic cancer.

Advanced/Metastatic Pancreatic Cancer (Epidemiology)

Pancreatic cancer is the 7th leading cause of cancer death worldwide and the 11th leading cause of cancer. The average lifetime incidence rate (ASR) is 7. It is 7 per 100,000 in Europe and 2.2 per 100,000 in Africa. The ASR was 0.81 per 100,000 men aged 15-24 years in India, varying across countries. In Moldova and the Republic of Latvia, it is 3 per 100,000 men. According to the American Cancer Society, by 2022, approximately 62,210 new cases of pancreatic cancer will be diagnosed in the United States (32,970 men and 29,240 women). The age-adjusted rate of new cases of pancreatic cancer increased by an average of 0.5% per year between 2010 and 2019. Pancreatic cancer is rare in people under 45 without risk factors such as a family history of pancreatic cancer and chronic pancreatitis. The chances of developing pancreatic cancer increase linearly with age after 50 years. It is diagnosed at an average age of 69 for whites and 65 for Black people. However, some data from a major cancer center showed that the average age at diagnosis dropped to 63 years for both men and women. Although pancreatic cancer accounts for only about 3% of all cancers in the country, it is the fourth leading cause of cancer death in both men and women, accounting for 8% of all deaths from the disease. According to the American Cancer Society, an estimated 47,050 Americans (24,640 men and 22,410 women) will die of pancreatic cancer in the United States in 2020. Between 2008 and 2017, pancreatic cancer mortality increased slightly (0.5% per year) among Black people. For whites, the decline was minimal (0.4% per year).

Advanced/Metastatic Pancreatic Cancer -Current Market Size & Forecast Trends

The pancreatic cancer market was valued at $2.1 billion in 2023, with an expected CAGR of ~12%, reaching approximately $8 billion by 2035, supported by advances in targeted and immunotherapeutic approaches.

Gemcitabine (Gem) has been the cornerstone of first-line PDAC treatment for more than ten years. It has been unsuccessful to combine single-agent GEMs with other cytotoxic/molecularly targeted medications or to change their pharmacokinetics in an effort to increase their efficacy. In the field of systemic therapy for advanced PDAC, advancements have recently been made. In comparison to single-agent stones, a number of chemotherapies have demonstrated promising outcomes: regimens like PEFG-PEXG-PDXG and GTX have a significant potential benefit in terms of survival and/or disease control, but occasionally at the expense of poor tolerability. The first phase III study, PRODIGE 4/ACCORD 11, showed a distinct advantage of multiple FOLFIRINOX chemotherapy regimens; however, the less favorable safety profile and profile of the enrolled population restrict the use of FOLFIRINOX in young, healthy patients with PDAC. To circumvent drug resistance by encasing pancreatic cancer cells in a synthetic matrix, paclitaxel has been conjugated with nanoparticles. In contrast to single beads, the combination of nab-paclitaxel and Gem demonstrated a statistically and clinically significant survival advantage, with significant improvements in all secondary endpoints, regardless of whether these were the primary mechanisms of action. Furthermore, new treatment options for advanced PDAC may now be available as a result of recent advancements in maintenance therapy, particularly in the current period of time in which patients can experience long-lasting disease control thanks to first-line treatment regimens that are incredibly effective.

Report Highlights

Advanced/Metastatic Pancreatic Cancer - Current Market Trends

Advanced/Metastatic Pancreatic Cancer - Current & Forecasted Cases across the G8 Countries

Advanced/Metastatic Pancreatic Cancer - Market Opportunities and Sales Potential for Agents

Advanced/Metastatic Pancreatic Cancer - Patient-based Market Forecast to 2035

Advanced/Metastatic Pancreatic Cancer - Untapped Business Opportunities

Advanced/Metastatic Pancreatic Cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced/Metastatic Pancreatic Cancer - KOLs Insight